Market closed
scPharmaceuticals/$SCPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About scPharmaceuticals
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.
Ticker
$SCPH
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
163
Website
SCPH Metrics
BasicAdvanced
$116M
-
-$1.91
0.39
-
Price and volume
Market cap
$116M
Beta
0.39
52-week high
$5.43
52-week low
$2.20
Average daily volume
573K
Financial strength
Current ratio
7.115
Quick ratio
5.942
Long term debt to equity
393.799
Total debt to equity
395.593
Interest coverage (TTM)
-8.56%
Management effectiveness
Return on assets (TTM)
-40.08%
Return on equity (TTM)
-336.97%
Valuation
Price to revenue (TTM)
2.818
Price to book
8.65
Price to tangible book (TTM)
8.65
Price to free cash flow (TTM)
-1.451
Growth
Revenue change (TTM)
167.28%
Earnings per share change (TTM)
34.39%
3-year earnings per share growth (CAGR)
23.11%
What the Analysts think about SCPH
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for scPharmaceuticals stock.
SCPH Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
SCPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
SCPH News
AllArticlesVideos
scPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 weeks ago
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewsWire·2 weeks ago
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for scPharmaceuticals stock?
scPharmaceuticals (SCPH) has a market cap of $116M as of April 05, 2025.
What is the P/E ratio for scPharmaceuticals stock?
The price to earnings (P/E) ratio for scPharmaceuticals (SCPH) stock is 0 as of April 05, 2025.
Does scPharmaceuticals stock pay dividends?
No, scPharmaceuticals (SCPH) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next scPharmaceuticals dividend payment date?
scPharmaceuticals (SCPH) stock does not pay dividends to its shareholders.
What is the beta indicator for scPharmaceuticals?
scPharmaceuticals (SCPH) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.